NCT05115292
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior CAR-T therapy or therapy targeting PD-L1/TGFBR2 (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with symptomatic central nervous system (CNS) metastases
https://ClinicalTrials.gov/show/NCT05115292